The promise of anti-angiogenic cancer therapy

Oehler, Martin K.; Bicknell, Roy

doi:10.1054/bjoc.1999.0991

Cited by 46 publications

(25 citation statements)

References 24 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…So anti-angiogenic therapy targeting the tumor blood supply has become a promising approach to combat HCC. 2,3 Endostatin, a 20 kD proteolytic fragment of the C-terminus of collagen XVIII, is one of the most potent angiogenesis inhibitors. 4 It induces the regression of a wide variety of established tumors of mouse, rat and human origins.…”

Section: Introductionmentioning

confidence: 99%

Combined endostatin and TRAIL gene transfer suppresses human hepatocellular carcinoma growth and angiogenesis in nude mice

Zhang

Qu²,

Cui³

et al. 2009

Cancer Biology & Therapy

View full text Add to dashboard Cite

Endostatin can inhibit tumor growth by blocking angiogenesis, whereas tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) may function as a soluble cytokine to selectively kill cancer cells without toxicity to most normal cells. To establish the combined anti-tumor therapeutic effect of endostatin and soluble TRAIL (sTRAIL), we performed intra-tumoral human endostatin and sTRAIL gene transfer using plasmid pVAX1 as a vector in a nude mouse model of human liver cancer. For subcutaneously inoculated human BEL7402 cancer, co-expression of both transgenes conferred marked anti-tumor activity with a significant reduction in tumor vessel density and an increase in apoptotic rates, which was accompanied with a strong activation of caspase-3. Importantly, combination therapy employing onehalf dose of endostatin and sTRAIL plasmids was more effective than single endostatin or sTRAIL therapy. These results indicate that a pVAX1-mediated combinatorial antiangiogenic and proapoptotic gene therapy approach involving endostatin and sTRAIL can be an effective novel form of treatment for human liver cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Combined endostatin and TRAIL gene transfer suppresses human hepatocellular carcinoma growth and angiogenesis in nude mice

Zhang

Qu²,

Cui³

et al. 2009

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…2,3 But this angiocytoic therapy is not yet applicable in clinical practice since no "specific" angiogenesis inhibitor is commercially available. 4,5 On the other hand, development of "specific" angiogenesis inhibitors has confronted challenges. Tumor angiogenesis is regulated by multiple angiogenic and anti-angiogenic growth factors secreted by tumor cells and stromal cells, the contents of those factors in a particular tumor substantially modify the effects of angiogenesis inhibitors.…”

Section: Introductionmentioning

confidence: 99%

Variable Sensitivity of Endothelial Cells to Epirubicin in Xenografts of Human Nasopharyngeal Carcinoma CNE-2 Cells

Zhang¹,

Zhu²,

Gao³

et al. 2002

Cancer Biology & Therapy

View full text Add to dashboard Cite

Conventional anticancer drugs show non-specific vascular toxicity, and using anticancer drugs as angiogenesis inhibitors was suggested. However, our previous study suggested that vascular endothelial growth factor (VEGF) protected endothelial cells against chemotherapy drugs in vitro. To further test whether the vascular toxicity of anticancer drugs is active in vivo, epirubicin was i.p. injected into nude mice with s.c. xenografts of human nasopharyngeal carcinoma CNE-2 once (one-day schedule) or once a day from day 1 to day 7 (seven-day schedule). At 48 hours after the single injection or the 7th injection tumors were removed for detection of apoptosis of vascular endothelial cells vessels and the content of VEGF in tumor tissues. The results showed that epirubicin damaged tumor microvessels when the drug was given as a single dose, whereas epirubicin lost its vascular toxicity when the drug was given continuously for seven days, accompanied by higher levels of VEGF in tumor tissues. These results suggest the sensitivity of endothelial cells lining tumor vessels is variable during chemotherapy, and the protective effect of VEGF on endothelial cells might be related to the schedule of administration.

show abstract

“…As therapies for human diseases become ever more sophisticated and specifically targeted, it becomes increasingly important to understand the potential limitations of extrapolating data from mice to humans. The literature is littered with examples of therapies that work well in mice but fail to provide similar efficacy in humans (2)(3)(4)(5)(6)(7). By focusing on some known differences between mouse and human immunology we hope to spur interest in this area and encourage others to note differences where they occur.…”

mentioning

confidence: 99%

Of Mice and Not Men: Differences between Mouse and Human Immunology

Mestas

Hughes

2004

The Journal of Immunology

2,985

2,322

View full text Add to dashboard Cite

Mice are the experimental tool of choice for the majority of immunologists and the study of their immune responses has yielded tremendous insight into the workings of the human immune system. However, as 65 million years of evolution might suggest, there are significant differences. Here we outline known discrepancies in both innate and adaptive immunity, including: balance of leukocyte subsets, defensins, Toll receptors, inducible NO synthase, the NK inhibitory receptor families Ly49 and KIR, FcR, Ig subsets, the B cell (BLNK, Btk, and λ5) and T cell (ZAP70 and common γ-chain) signaling pathway components, Thy-1, γδ T cells, cytokines and cytokine receptors, Th1/Th2 differentiation, costimulatory molecule expression and function, Ag-presenting function of endothelial cells, and chemokine and chemokine receptor expression. We also provide examples, such as multiple sclerosis and delayed-type hypersensitivity, where complex multicomponent processes differ. Such differences should be taken into account when using mice as preclinical models of human disease.

show abstract

The promise of anti-angiogenic cancer therapy

Cited by 46 publications

References 24 publications

Combined endostatin and TRAIL gene transfer suppresses human hepatocellular carcinoma growth and angiogenesis in nude mice

Combined endostatin and TRAIL gene transfer suppresses human hepatocellular carcinoma growth and angiogenesis in nude mice

Variable Sensitivity of Endothelial Cells to Epirubicin in Xenografts of Human Nasopharyngeal Carcinoma CNE-2 Cells

Of Mice and Not Men: Differences between Mouse and Human Immunology

Contact Info

Product

Resources

About